Baricitinib

Details:

Baricitinib (olumiant) is a selective JAK2 and JAK1 inhibitor, which is less effective against JanusKinase and jak3orTYK2. The kinase and its related signal transducer and activator of transcription (JAK-STAT) are the main intracellular pathways that control the amplitude and duration of cytokine and type I and type II cytokine receptor signaling. These receptors lack the intrinsic enzymatic activity signal transduction that can be mediated; Janus kinase\signal transduction and transcription activator are phosphorylated by JAK enzyme, leading to STAT activation. Several inflammatory Chemicalbook factors are involved in the pathogenesis of RA, including IL-6, granulocyte macrophage colony stimulating factor, (GM-CSF) factor. The interferon signal passes through the JAK-STAT signal pathway. Therefore, JAK1 and JAK2 inhibitors can target multiple RA-related cytokine pathways, thereby reducing the activation and proliferation of inflammatory cells and key immune cells. Baricitinib has no effect on JAK3. JAK3 may be related to common gamma chain receptors. Common γ chain cytokines include IL-15 and IL-21, which mainly regulate the activation, function and proliferation of lymphocytes.

For adults to treat moderately to severely active rheumatoid arthritis (RA), patients who are intolerant to one or more anti-rheumatic drugs can be treated with this product. This product can be treated with single agent or with methotrexate Combination therapy with chlorin. The efficacy of Chemicalbookbaricitinib in the treatment of psoriasis, diabetic nephropathy, atopic dermatitis, systemic lupus erythematosus and other diseases is currently in the phase II clinical stage. 2. Used in the field of scientific research and chemical reagents